Last reviewed · How we verify
NCT04922450
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2 trial testing PD-1 inhibitor in Head and Neck Cancer in 53 participants. Status unknown.
20 January 2023
Quick facts
| Lead sponsor | Hunan Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 53 |
| Start date | 20 January 2021 |
| Primary completion | 20 January 2023 |
| Estimated completion | 20 January 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- PD-1 inhibitor — full drug profile →
- Albumin Paclitaxel — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
Sponsor
Hunan Cancer Hospital
Who can join
Adults 18 to 65, any sex, with Head and Neck Cancer or Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this single-arm study, pathologically confirmed advanced head and neck squamous cell carcinoma will be enrolled to investigate the efficacy and safety of Camrelizumab in combination With albumin paclitaxel and cisplatin.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization.
Rajeev-Kumar G, Pitroda SP. · · 2023 · cited 22× · PMID 36563632 · DOI 10.1016/j.neo.2022.100867 -
Advances in nanomaterials for the diagnosis and treatment of head and neck cancers: A review.
Yu C, Li L, Wang S, Xu Y, et al · · 2023 · cited 19× · PMID 37056270 · DOI 10.1016/j.bioactmat.2022.08.010 -
Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.
Bhattacharjee B, Syeda AF, Rynjah D, Hussain SM, et al · · 2023 · cited 17× · PMID 37205904 · DOI 10.3389/fphar.2023.1174330 -
Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Zheng S, Feng Y, Li C, Zhang J, et al · · 2023 · cited 5× · PMID 36943658 · DOI 10.1007/s40487-023-00226-7 -
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David E, Perez C, Rodallec A. · · 2022 · cited 2× · PMID 36365144 · DOI 10.3390/pharmaceutics14112326
Verify or expand the search:
- PubMed search for NCT04922450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PD-1 inhibitor
Trials testing the same drug.
- NCT07182565 — Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcin · Phase 1, PHASE2 · recruiting
- NCT07007182 — Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07072351 — Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade · Phase 1, PHASE2 · recruiting
- NCT07142200 — A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy a · Phase 2 · not yet recruiting
- NCT06841679 — Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi · Phase 2, PHASE3 · recruiting
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other Hunan Cancer Hospital trials
Trials by the same sponsor.
- NCT07314216 — Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcin · Phase 2 · not yet recruiting
- NCT07083687 — Lorlatinib in ROS1+ NSCLC With Brain Metastasis · Phase 2 · not yet recruiting
- NCT07098026 — Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer · NA · recruiting
- NCT06840704 — Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer · Phase 3 · recruiting
- NCT06788002 — LDRT and Chemoimmunotherapy in NPC With Liver Metastasis · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04922450 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunan Cancer Hospital
- Last refreshed: 10 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04922450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing